knowledge -WSS

knowledge

author：Wikipedia 2025-09-07 06:40:38 - browse：528

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Will Ozempic

leisure time

WSS

Pharmacists can make shortage drugs, but at what cost?

Lawmakers consider Medicare pay reforms for doctors

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

FDA gives detailed accounting of AI

Solve the antibiotic resistance crisis with preventive drugs

The EU Joint Clinical Assessment needs to live up to its promise

knowledge

knowledge

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Stop the failed accountable care organization experiment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

First Opinion Podcast: Long Covid needs a new approach

Virginia high school admissions case could be legal follow

STAT Readout Newsletter: Today's biggest biotech updates

Apple is now the first public company to be valued at $3 trillion

Plastic surgeons increase patient psychiatric screenings

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Asbestos, a deadly carcinogen, banned by EPA

focus

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Neuroscience’s long legacy of racism

Baby aspirin cuts fat buildup in liver disease patients, in small study

Physicians and social media: If you see something, say something?

UnitedHealth increases loan offers after Change Healthcare outage

U.K. researchers warn about biases in medical devices, algorithms

leisure time

entertainment

leisure time

focus